Document Detail

Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
MedLine Citation:
PMID:  21123825     Owner:  NLM     Status:  In-Data-Review    
Extranodal NK/T-cell lymphoma, nasal type, is a rare and highly aggressive disease with a grim prognosis. No therapeutic strategy is currently identified in relapsing patients. We report the results of a French prospective phase II trial of an L-asparaginase-containing regimen in 19 patients with relapsed or refractory disease treated in 13 centers. Eleven patients were in relapse and 8 patients were refractory to their first line of treatment. L-Asparaginase-based treatment yielded objective responses in 14 of the 18 evaluable patients after 3 cycles. Eleven patients entered complete remission (61%), and only 4 of them relapsed. The median overall survival time was 1 year, with a median response duration of 12 months. The main adverse events were hepatitis, cytopenia, and allergy. The absence of antiasparaginase antibodies and the disappearance of Epstein-Barr virus serum DNA were significantly associated with a better outcome. These data confirm the excellent activity of L-asparaginase-containing regimens in extranodal NK/T-cell lymphoma. L-Asparaginase-based treatment should thus be considered for salvage therapy, especially in patients with disseminated disease. First-line L-asparaginase combination therapy for extranodal NK/T-cell lymphoma warrants evaluation in prospective trials. This trial is registered at as #NCT00283985.
Arnaud Jaccard; Nathalie Gachard; Benoit Marin; Sylvie Rogez; Marie Audrain; Felipe Suarez; Hervé Tilly; Franck Morschhauser; Catherine Thieblemont; Loic Ysebaert; Alain Devidas; Barbara Petit; Laurence de Leval; Philippe Gaulard; Jean Feuillard; Dominique Bordessoule; Olivier Hermine;
Related Documents :
21148615 - Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, no...
2161175 - Spinal cord toxicity complicating treatment with cisplatin and etoposide.
2993535 - High-dose cisplatin in hypertonic saline in refractory ovarian cancer.
21431095 - Clinical impact of tumor regression grade after preoperative chemoradiation for locally...
8200375 - A long-term evaluation of the cin-lesions. a clinicopathological study.
2720605 - Cancer of the breast in poor black women.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-12-01
Journal Detail:
Title:  Blood     Volume:  117     ISSN:  1528-0020     ISO Abbreviation:  Blood     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-02-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1834-9     Citation Subset:  AIM; IM    
Service d'Hématologie et de Thérapie Cellulaire, Centre Hospitalier Universitaire (CHU) Limoges, Université et Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR) 6101, Limoges, France.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Lionel Galicier / ; Pauline Brice / ; Jean-Baptiste Golfier / ; Christian Gisselbrecht / ; Bertrand Joly / ; Olivier Fitoussi / ; Paul Coppo / ; Bernadette Corront / ; Isabelle Cumin / ; Jean-François Rossi / ; Valérie Coiteux / ; Pascal Lenain / ; Guy Laurent / ; Christian Recher / ; Mathilde Hunault / ; Noel Milpied / ; Kamal Bouabdallah / ; Thibault Legay / ; Stephane Girault / ; Pascal Turlure / ; Natacha Dmytruck / ; Stephane Moreau / ; Marie-Pierre Gourin / ; Mohamed Touati / ; Liliane Remenieras /

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chap...
Next Document:  SYK regulates B-cell migration by phosphorylation of the F-actin interacting protein SWAP-70.